论文部分内容阅读
急性白血病(急白)是一种造血系统肿瘤性疾病,由于新的抗白血病药物不断发现,并采用联合化疗诱导方案、巩固强化治疗、中枢神经系统白血病(CNSL)的预防、维持治疗,并加强了支持疗法等,预后已完全改观.目前儿童急性淋巴细胞白血病(急淋)完全缓解(CR)率最高已达95%以上,有报道用长春新碱(VCR)、L-门冬酰胺酶(L ASP)、强的松(PRD)治疗儿童急淋724例的8年生存率达56%。无病生存率52%.近年来成人急淋的疗效也逐渐接近儿童,CR 率达80%以
Acute leukemia (acute white) is a hematopoietic neoplastic disease that continues to be discovered as a result of new anti-leukemia drugs and the use of a combination chemotherapy regimen to consolidate intensive care and CNSL prevention and maintenance treatment and to strengthen Supportive therapy, the prognosis has been completely changed.At present, the highest rate of complete remission (CR) in children with acute lymphoblastic leukemia has reached more than 95%, it has been reported with vincristine (VCR), L- asparaginase L ASP), and 824-year survival rate of prednisone (PRD) in children with acute leaching 724 cases was 56%. Disease-free survival rate of 52%. In recent years, the efficacy of adult acute lymphoma also gradually close to children, CR rate of 80%